Jean‐charles Fruchart

Jean‐charles Fruchart's AcademicInfluence.com Rankings

Philosophy

#3070

World Rank

#5045

Historical Rank

Logic

#935

World Rank

#1519

Historical Rank

philosophy Degrees

Jean‐charles Fruchart

Biology

#3697

World Rank

#5617

Historical Rank

Biochemistry

#358

World Rank

#430

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Jean‐charles Fruchart's Degrees

PhD Biochemistry Université Paris Cité
Doctorate Medicine Université Paris Cité

Why Is Jean‐charles Fruchart Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jean‐charles Fruchart's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As (2009) (11411)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. (2005) (3308)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. (2006) (1952)
Mechanism of action of fibrates on lipid and lipoprotein metabolism. (1998) (1615)
The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* (1997) (1292)
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators (1998) (1064)
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing (2001) (923)
Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation (2000) (917)
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* (1999) (917)
Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* (1998) (866)
PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway (2001) (833)
Peroxisome proliferator-activated receptors in inflammation control. (2001) (777)
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. (2007) (767)
Sorting out the roles of PPARα in energy metabolism and vascular homeostasis (2006) (753)
Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice (1998) (632)
Therapeutic roles of peroxisome proliferator-activated receptor agonists. (2005) (624)
Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* (2000) (624)
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. (2004) (557)
An Easier, Reproducible, and Mass‐Production Method to Study the Blood–Brain Barrier In Vitro (1990) (538)
Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. (1999) (535)
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. (2004) (534)
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity (2020) (528)
The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice* (2006) (517)
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. (2008) (473)
Atherogenic Lipoprotein Particles in Atherosclerosis (2004) (472)
Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice* (1997) (456)
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. (1998) (456)
Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. (1998) (455)
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. (2019) (449)
CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. (2000) (445)
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. (2000) (435)
Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators* (2000) (435)
Regulation of Peroxisome Proliferator-Activated Receptor γ Expression by Adipocyte Differentiation and Determination Factor 1/Sterol Regulatory Element Binding Protein 1: Implications for Adipocyte Differentiation and Metabolism (1999) (431)
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. (2001) (428)
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. (1995) (423)
Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis (2002) (414)
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes (2006) (409)
C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease: The PRIME Study (2003) (409)
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. (2006) (404)
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. (2003) (396)
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study (2006) (383)
Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis (1999) (382)
New Risk Factors for Atherosclerosis and Patient Risk Assessment (2004) (346)
Apolipoprotein A-I containing lipoproteins in coronary artery disease. (1987) (336)
Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. (1987) (330)
The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates* (1998) (325)
PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter (1998) (317)
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. (2002) (317)
Safety issues and prospects for future generations of PPAR modulators. (2007) (288)
Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation (2003) (287)
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C* (2004) (265)
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. (1996) (263)
Increased ABCA1 activity protects against atherosclerosis. (2002) (262)
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients (2008) (261)
Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators (2000) (259)
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. (2003) (258)
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. (2006) (253)
Peroxisome Proliferator-Activated Receptor-α Activation as a Mechanism of Preventive Neuroprotection Induced by Chronic Fenofibrate Treatment (2003) (252)
Protection Against Atherogenesis in Mice Mediated by Human Apolipoprotein A-IV (1996) (251)
Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. (1994) (251)
The role of PPARs in atherosclerosis. (2002) (249)
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study (2018) (244)
Glucose regulates the expression of the farnesoid X receptor in liver. (2004) (242)
The orphan nuclear receptor RORα is a negative regulator of the inflammatory response (2001) (237)
Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes (1987) (225)
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. (2002) (225)
Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. (1996) (225)
The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition* (2005) (224)
Bovine Brain Endothelial Cells Express Tight Junctions and Monoamine Oxidase Activity in Long‐Term Culture (1989) (221)
Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α Activators* (2003) (217)
An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer (1999) (216)
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice (2001) (211)
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. (2004) (209)
PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance (2001) (208)
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. (2000) (208)
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. (1998) (207)
The Orphan Nuclear Receptor Rev-Erbα Is a Peroxisome Proliferator-activated Receptor (PPAR) γ Target Gene and Promotes PPARγ-induced Adipocyte Differentiation* (2003) (206)
Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. (1990) (205)
p300 Interacts with the N- and C-terminal Part of PPARγ2 in a Ligand-independent and -dependent Manner, Respectively* (1999) (200)
FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. (2003) (197)
Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice* (2002) (195)
Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. (2000) (194)
Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. (2009) (193)
Transcriptional control of adipogenesis. (1998) (191)
PPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages (2001) (186)
Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. (2006) (183)
Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. (1999) (183)
Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study (2002) (182)
Drug Transfer Across the Blood‐Brain Barrier: Correlation Between In Vitro and In Vivo Models (1992) (181)
Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Témoin sur l'Infarctus du Myocarde. (1995) (179)
Adipophilin Enhances Lipid Accumulation and Prevents Lipid Efflux From THP-1 Macrophages: Potential Role in Atherogenesis (2004) (178)
PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism (2002) (176)
Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. (1995) (176)
Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. (1999) (176)
Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. (2003) (174)
In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I,A-II. (1991) (174)
Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. (2002) (174)
PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome (2006) (170)
Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. (2002) (169)
The role of fibric acids in atherosclerosis (2001) (166)
Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. (1999) (165)
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. (2005) (164)
Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. (1992) (164)
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors (2007) (159)
Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. (1996) (158)
Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. (2005) (158)
Residual macrovascular risk in 2013: what have we learned? (2014) (157)
Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. (2000) (157)
Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β* (2001) (153)
A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. (1999) (153)
Oxidized phospholipids activate PPARα in a phospholipase A2‐dependent manner (2000) (152)
Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–&agr; Activators: Clinical and Experimental Evidence (2006) (151)
Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. (1999) (149)
Drug transfer across the blood-brain barrier: Correlation between “in vitro” and “in vivo” models (1992) (146)
Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. (1996) (145)
Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. (1987) (145)
Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. (1998) (144)
Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator–Activated Receptor-α via Inhibition of the Protein Kinase C Signaling Pathway (2006) (143)
Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. (1997) (142)
Apolipoprotein A-II, HDL metabolism and atherosclerosis. (2002) (140)
The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. (2001) (138)
Transcriptional Regulation of Apolipoprotein C-III Gene Expression by the Orphan Nuclear Receptor RORα* (2001) (138)
Transcriptional Regulation of Apolipoprotein A-I Gene Expression by the Nuclear Receptor RORα* (1997) (138)
Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists (2013) (137)
Circadian and Glucocorticoid Regulation of Rev-erbα Expression in Liver. (2000) (136)
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. (2006) (135)
Liver X Receptor Activation Controls Intracellular Cholesterol Trafficking and Esterification in Human Macrophages (2005) (135)
Peroxisome Proliferator-activated Receptor α Induces Hepatic Expression of the Human Bile Acid Glucuronidating UDP-glucuronosyltransferase 2B4 Enzyme* (2003) (134)
Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. (1991) (133)
Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. (1999) (132)
PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. (1998) (132)
Low‐Density Lipoprotein Receptor on Endothelium of Brain Capillaries (1989) (132)
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. (2004) (131)
Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. (1995) (131)
Plasma cystatin-C and development of coronary heart disease: The PRIME Study. (2006) (126)
Increased triglyceride levels in shift workers. (1992) (125)
Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. (1992) (125)
The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor α and γ Target Gene* (2003) (124)
Peroxisome Proliferator-activated Receptor α (PPARα) Turnover by the Ubiquitin-Proteasome System Controls the Ligand-induced Expression Level of Its Target Genes* (2002) (123)
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. (2016) (123)
Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator–Activated Receptor &agr; Modulation (2005) (122)
Peroxisome Proliferator-Activated Receptor &agr; Reduces Cholesterol Esterification in Macrophages (2003) (122)
Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. (1995) (122)
Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. (1996) (122)
Oxidation of lipoproteins and atherosclerosis. (1991) (121)
The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. (2003) (120)
Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism☆ (2001) (119)
PPARS, metabolic disease and atherosclerosis. (2001) (118)
Short term response of circulating leptin to feeding and fasting in man: influence of circadian cycle (1998) (117)
Leptin response to carbohydrate or fat meal and association with subsequent satiety and energy intake. (1999) (117)
Familial hypoalphalipoproteinemia in premature coronary artery disease. (1993) (117)
PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. (2001) (116)
The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. (1989) (115)
Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor (2005) (114)
Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. (1990) (113)
Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. (1987) (113)
Influence of serum amyloid A on cholesterol esterification in human plasma. (1989) (111)
DNA Binding-Independent Induction of IκBα Gene Transcription by PPARα (2002) (110)
Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. (1996) (109)
The farnesoid X receptor induces very low density lipoprotein receptor gene expression (2004) (107)
Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate* (2001) (107)
Peroxisome Proliferator–Activated Receptor α Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets (2006) (106)
HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age. (1993) (106)
Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications (2003) (106)
Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. (2005) (105)
Coronary Heart Disease: Reducing The Risk: A Worldwide View (1999) (105)
Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis (2009) (104)
Black-white differences in serum Lp(a) lipoprotein levels. (1987) (104)
Liver X Receptor Activation Potentiates the Lipopolysaccharide Response in Human Macrophages (2007) (104)
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis (2006) (100)
Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. (2003) (97)
3‐Hydroxy‐3‐methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C‐III and lipoprotein lipase (1999) (97)
PPARa activators improve insulin sensitivity and reduce adiposity (2000) (97)
Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo (2006) (93)
Peroxisome Proliferator–Activated Receptor &agr; Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR-&agr; Activation Properties (2004) (93)
Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin (1991) (93)
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia (2017) (92)
Peroxisome Proliferator–activated Receptor Activators Inhibit Oxidized Low-density Lipoprotein–induced Endothelin-1 Secretion in Endothelial Cells (2002) (92)
Transient impairment of the adaptive response to fasting in FXR‐deficient mice (2005) (90)
Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface. (1995) (90)
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. (2004) (90)
Human Plasma Lipoproteins (1989) (89)
Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat (1999) (89)
The Liver X Receptor Ligand T0901317 Down-regulates APOA5 Gene Expression through Activation of SREBP-1c* (2004) (89)
Cloning and sequencing of cDNAs encoding the human hepatocyte nuclear factor 4 indicate the presence of two isoforms in human liver. (1994) (88)
p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. (1999) (88)
Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function (2003) (88)
Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates (1997) (88)
Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. (2000) (88)
The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor α (2004) (87)
Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. (2004) (87)
Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. (1989) (85)
Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations, and cholesterol efflux capacity. (2002) (84)
Peroxisome Proliferator-activated Receptor α Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil* (2001) (84)
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential (2019) (84)
Genetic Determinants of Responsiveness to the HMG‐CoA Reductase Inhibitor Fluvastatin in Patients With Molecularly Defined Heterozygous Familial Hypercholesterolemia (1993) (83)
Induction of the Fatty Acid Transport Protein 1 and Acyl-CoA Synthase Genes by Dimer-selective Rexinoids Suggests That the Peroxisome Proliferator-activated Receptor-Retinoid X Receptor Heterodimer Is Their Molecular Target* (2000) (83)
Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cells. (1991) (82)
Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice (2004) (82)
Peroxisome proliferator‐activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages (2002) (82)
Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. (2000) (82)
Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and lipoprotein particles. (1993) (81)
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes (2005) (81)
Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. (2001) (80)
Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid. (1996) (80)
Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. (1997) (79)
The effect of moderate alcohol intake on serum apolipoprotein A-I-containing lipoproteins and lipoprotein (a). (1991) (78)
Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice. (2000) (78)
A selective bi-site immunoenzymatic procedure for human Lp[a] lipoprotein quantification using monoclonal antibodies against apo[a] and apoB. (1989) (77)
Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. (2000) (76)
The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). (1997) (76)
Combination lipid therapy in type 2 diabetes. (2010) (75)
Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. (2008) (75)
PPARs in Inflammation, Atherosclerosis and Thrombosis (2001) (75)
Inhibitory Effects of Specific Apolipoprotein C-III Isoforms on the Binding of Triglyceride-rich Lipoproteins to the Lipolysis-stimulated Receptor* (1997) (75)
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. (2001) (75)
Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver. (2000) (74)
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. (2006) (73)
Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. (1993) (71)
Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. (2005) (71)
Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of β‐oxidation (2006) (71)
PPAR&agr;, but not PPAR&ggr;, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia (2005) (71)
Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. (1997) (70)
Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C activation. (1990) (70)
Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. (1991) (70)
The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. (2008) (69)
Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. (1995) (68)
Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles. (1995) (68)
Hepatic Expression of the UGT1A9 Gene Is Governed by Hepatocyte Nuclear Factor 4α (2005) (67)
The epitopes of apolipoprotein A-I define distinct structural domains including a mobile middle region. (1991) (67)
The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia (2006) (67)
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall (2001) (65)
Lipoprotein abnormalities in chronic haemodialysis patients. (1988) (65)
Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency. (1996) (65)
Circadian variation of postprandial lipemia. (1997) (65)
Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. (1990) (65)
n-3 polyunsaturated fatty acids raise low-density lipoproteins, high-density lipoprotein 2, and plasminogen-activator inhibitor in healthy young men. (1991) (64)
The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. (2003) (64)
Effect of alcohol intake on human apolipoprotein A-I-containing lipoprotein subfractions. (1990) (63)
Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitis. (2005) (62)
Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells. (1999) (62)
Enhanced cholesterol efflux promotion in well-trained soccer players. (2004) (62)
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. (2006) (61)
Transcriptional Regulation of Human Rev-erbα Gene Expression by the Orphan Nuclear Receptor Retinoic Acid-related Orphan Receptor α* (2002) (61)
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists (2007) (61)
Extracellular Human Thioredoxin-1 Inhibits Lipopolysaccharide-induced Interleukin-1β Expression in Human Monocyte-derived Macrophages* (2005) (60)
Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe* (2004) (60)
Lipid Free Apolipoprotein E Binds to the Class B Type I Scavenger Receptor I (SR-BI) and Enhances Cholesteryl Ester Uptake from Lipoproteins* (2002) (59)
Phenylpropanoids from Ballota nigra L. inhibit in vitro LDL peroxidation (2000) (58)
Hawthorn extracts inhibit LDL oxidation. (2003) (58)
Transgenic rabbits expressing human apolipoprotein A-I in the liver. (1996) (58)
Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. European Atherosclerosis Research Study. (1994) (58)
Modulation of Cholesterol Efflux from Fu5AH Hepatoma Cells by the Apolipoprotein Content of High Density Lipoprotein Particles. (1995) (58)
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. (2004) (57)
Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. (2002) (57)
Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. (1989) (57)
HDL and triglyceride as therapeutic targets (2002) (56)
Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. (1995) (56)
DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. (2002) (56)
Purification of an apolipoprotein A binding protein from mouse adipose cells. (1990) (56)
Preformed PAF‐acether and lyso PAF‐acether are bound to blood lipoproteins (1988) (56)
The human fatty acid transport protein-1 (SLC27A1; FATP-1) cDNA and gene: organization, chromosomal localization, and expression. (2000) (55)
Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. (1990) (55)
Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. (1999) (54)
Glucocorticoids induce the expression of the leptin gene through a non-classical mechanism of transcriptional activation. (1998) (54)
Decreased Susceptibility to Diet-Induced Atherosclerosis in Human Apolipoprotein A-II Transgenic Mice (2000) (54)
Structure-activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation model. (1999) (54)
Biochemical characterization of the three major subclasses of lipoprotein A-I preparatively isolated from human plasma. (1993) (54)
Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolemia among postmenopausal women (1995) (54)
High-density lipoprotein subclasses and apolipoprotein A-I. (1999) (54)
Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. (2001) (53)
Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (ApoA-I) variants with murine adipocytes and macrophages. Evidence for reduced cholesterol efflux promotion by apoA-I(Pro165-->Arg). (1993) (53)
Thioredoxin reductase 1 is upregulated in atherosclerotic plaques: specific induction of the promoter in human macrophages by oxidized low-density lipoproteins. (2004) (52)
Lowering of HDL2-cholesterol and lipoprotein A-I particle levels by increasing the ratio of polyunsaturated to saturated fatty acids. (1991) (52)
Heterogeneity of High Density Lipoprotein Particles (1993) (52)
Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor RORα (2005) (52)
Apolipoprotein E-∈A allele and Alzheimer's disease (1993) (52)
Molecular Mechanism of the Blockade of Plasma Cholesteryl Ester Transfer Protein by Its Physiological Inhibitor Apolipoprotein CI* (2005) (51)
Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease. (1999) (51)
Paullinia pinnata Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms (2006) (51)
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group. (1993) (50)
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. (2005) (49)
Apolipoprotein A-I domains involved in the activation of lecithin:cholesterol acyltransferase. Importance of the central domain. (1993) (49)
Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. (1996) (49)
The role of the orphan nuclear receptor Rev-Erbα in adipocyte differentiation and function (2005) (48)
Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. (2000) (48)
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. (2022) (48)
Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD. (1992) (48)
Oxidized phospholipids activate PPARα in a phospholipase A2-dependent manner (2000) (47)
Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. (1995) (47)
The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. (2004) (46)
Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. (2000) (46)
Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i) (2010) (45)
Polymorphisms of the apolipoprotein B and E genes and their relationship to plasma lipid variables in healthy Chinese men (1993) (45)
Identification of specific amphipathic alpha-helical sequence of human apolipoprotein A-IV involved in lecithin:cholesterol acyltransferase activation. (1994) (44)
[Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control]. (2002) (44)
Apolipoprotein AII enrichment of HDL enhances their affinity for class B type I scavenger receptor but inhibits specific cholesteryl ester uptake. (2000) (44)
Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content (2020) (44)
Natural phenylpropanoids protect endothelial cells against oxidized LDL-induced cytotoxicity. (2003) (43)
Postprandial Leptin Response to Carbohydrate and Fat Meals in Obese Women (2003) (43)
The PPARα Activator Fenofibrate Slows Down the Progression of the Left Ventricular Dysfunction in Porcine Tachycardia-Induced Cardiomyopathy (2007) (43)
Leptin, a pleiotropic hormone: physiology, pharmacology, and strategies for discovery of leptin modulators. (1998) (43)
PPAR alpha, fibrates, lipid metabolism and inflammation. (2004) (43)
Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. (1999) (42)
Farnesoid X receptor represses hepatic lipase gene expression Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.M400221-JLR200 (2004) (42)
Di‐tert‐butylhydroxylated flavonoids protect endothelial cells against oxidized LDL‐induced cytotoxicity (2001) (42)
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. (2005) (42)
Relationship in adipose cells between the presence of receptor sites for high density lipoproteins and the promotion of reverse cholesterol transport. (1987) (42)
Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha. (2002) (41)
Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. (1993) (40)
Alpha-Tocopherol But Not Beta-Tocopherol Inhibits Thrombin-Induced PKC Activation and Endothelin Secretion in Endothelial Cells (1998) (40)
Lack of association between genetic variations of apo A-I-C-III-A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study. (1999) (39)
Systemic tissue inhibitor of metalloproteinase‐1 gene delivery reduces neointimal hyperplasia in balloon‐injured rat carotid artery (2002) (39)
Plasma cholesterol and endogenous cholesterol synthesis during refeeding in anorexia nervosa. (2000) (38)
PPARs: a new target for neuroprotection (2005) (38)
Immunological properties of apoB-containing lipoprotein particles in human atherosclerotic arteries. (1993) (38)
Structural domain of apolipoprotein A-I involved in its interaction with cells. (1994) (38)
Is apolipoprotein A5 a novel regulator of triglyceride‐rich lipoproteins? (2006) (38)
Rapid quantification of alpha-tocopherol in plasma and low- and high-density lipoproteins. (1996) (38)
Cigarette smoking is associated with differences in nutritional habits and related to lipoprotein alterations independently of food and alcohol intake. (1996) (38)
FXR‐deficiency confers increased susceptibility to torpor (2007) (37)
Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk. (1994) (37)
Different ways to regulate the PPARα stability (2004) (37)
Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. (2005) (37)
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease (2006) (37)
Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes (2004) (37)
Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia. (2004) (36)
Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease. (1991) (36)
Quantitative determination of different apolipoprotein B containing lipoproteins by an enzyme linked immunosorbent assay: apo B with apo C-III and apo B with apo E. (1991) (36)
High-density lipoprotein particles in octogenarians. (1991) (36)
Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia (2008) (36)
Effects of different dietary cholesterol concentrations on lipoprotein plasma concentrations and on cholesterol efflux from Fu5AH cells. (1998) (36)
Novel Peroxisome Proliferator Activated Receptor–α Agonists (2007) (36)
Fatty acid composition of brain capillary endothelial cells: effect of the coculture with astrocytes. (1995) (35)
Enzyme immunoassay for human apolipoprotein B, the major protein moiety in low-density- and very-low-density lipoproteins. (1978) (35)
DNA polymorphisms of human apolipoprotein A‐IV gene: frequency and effects on lipid, lipoprotein and apolipoprotein levels in a French population (1994) (35)
Entry of polyunsaturated fatty acids into the brain: evidence that high-density lipoprotein-induced methylation of phosphatidylethanolamine and phospholipase A2 are involved. (1996) (35)
A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells. (1998) (35)
Liver X Receptor Activation Induces the Uptake of Cholesteryl Esters From High Density Lipoproteins in Primary Human Macrophages (2008) (34)
Selective uptake of cholesteryl esters from high-density lipoprotein-derived LpA-I and LpA-I:A-II particles by hepatic cells in culture. (1998) (34)
Effect of smoking cessation on lipoprotein A-I and lipoprotein A-I:A-II levels. (1997) (34)
Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia. (1991) (34)
Expression of Human Apolipoprotein A-I/C-III/A-IV Gene Cluster in Mice Induces Hyperlipidemia but Reduces Atherogenesis (2000) (34)
Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. (2003) (34)
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening. (1988) (33)
Pinus pinaster oil affects lipoprotein metabolism in apolipoprotein E-deficient mice. (1999) (33)
Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. (1997) (33)
Pleiotropic effects of fibrates (2005) (32)
Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. (2003) (32)
The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. (1990) (31)
HDL heterogeneity and atherosclerosis. (1996) (31)
Six DNA polymorphisms in the low density lipoprotein receptor gene: their genetic relationship and an example of their use for identifying affected relatives of patients with familial hypercholesterolaemia. (1993) (31)
Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid. Absence of effects on apolipoprotein A-II gene expression. (1994) (31)
Implications of emerging risk factors for therapeutic intervention. (2005) (31)
Effect of fenofibrate treatment on type III hyperlipoproteinemia. (1987) (30)
VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein. (1998) (30)
Characterization of a monoclonal antibody that binds to apolipoprotein E and to lipoprotein of human plasma containing apo E. Applications to ELISA quantification of plasma apo E. (1988) (30)
High density lipoproteins and coronary heart disease. Future prospects in gene therapy. (1998) (30)
SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295R. (2003) (30)
Analysis of phospholipid transfer during HDL binding to platelets using a fluorescent analog of phosphatidylcholine. (1987) (29)
[Molecular mechanism of action of the fibrates]. (1999) (29)
Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here? (2010) (29)
Apolipoprotein A-I-containing lipoproteins and atherosclerosis (1995) (29)
Abnormal capacity to induce cholesterol efflux and a new LpA-I pre-beta particle in type 2 diabetic patients. (1999) (29)
Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from LpA-I compared with LpA-I:A-II lipoprotein particles. (2003) (28)
Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry. (2000) (28)
In vitro reconstituted blood-brain barrier (1992) (28)
Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. (2002) (28)
Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR. (2006) (28)
Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients. (1997) (27)
The role of the orphan nuclear receptor Rev-Erb alpha in adipocyte differentiation and function. (2005) (27)
Natural phenylpropanoids inhibit lipoprotein‐induced endothelin‐1 secretion by endothelial cells (2004) (27)
Melatonin related compounds inhibit lipid peroxidation during copper or free radical‐induced LDL oxidation (2002) (27)
Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. (2002) (27)
Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein. (1996) (26)
Characterization of angiogenin receptors on bovine brain capillary endothelial cells. (1991) (26)
Kinetic study of serum lipoproteins, total cholesterol and triacylglycerides in various models of experimental rodent malaria. (1980) (25)
Relation of Arteriographically Defined Coronary Artery Disease to Serum Lipoprotein Particles Mapped With Monoclonal Antibodies (1991) (25)
Two-site enzyme immunoassay of cholesteryl ester transfer protein with monoclonal and oligoclonal antibodies. (1994) (25)
Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome (2007) (25)
Interaction of LDL, Lp[a], and reduced Lp[a] with monoclonal antibodies against apoB. (1988) (25)
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. (2007) (25)
Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages. (2006) (25)
Lipoprotein metabolism in marasmic children of northern Mauritania. (1993) (24)
Influence of mental stress and circadian cycle on postprandial lipemia. (1999) (24)
Heterozygosity for ABCA1 gene mutations: effects on enzymes, apolipoproteins and lipoprotein particle size. (2003) (24)
Fenofibrate Increases Homocystinemia Through a PPAR&agr;-Mediated Mechanism (2004) (24)
Serum apolipoprotein A-II, a biochemical indicator of alcohol abuse. (1984) (23)
Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction. (1995) (23)
HDL heterogeneity and coronary heart disease. (1991) (23)
Protein kinase C-dependent desensitization of HDL3-activated phospholipase C in human platelets. (1994) (23)
Liver X receptors: new players in atherogenesis? (2003) (23)
Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. (1996) (23)
Apolipoprotein A-I-Containing Particles and Reverse Cholesterol Transport in IDDM (1992) (23)
Quantitative determination of human plasma apolipoprotein A-II by a non competitive enzyme-linked immunosorbent assay. (1986) (23)
4-Mercaptoimidazoles derived from the naturally occurring antioxidant ovothiols 1. Antioxidant properties (2000) (23)
Enzyme-linked immunosorbent assay for human proapolipoprotein A-I using specific antibodies against synthetic peptide. (1988) (22)
Pertussis toxin sensitive G-protein coupling of HDL receptor to phospholipase C in human platelets. (1992) (22)
Glucose regulates LXRα subcellular localization and function in rat pancreatic β-cells (2006) (22)
Functional characterization of human recombinant apolipoprotein AIV produced in Escherichia coli. (1991) (22)
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. (1996) (22)
Latex immunoassay of human serum Lp(a+) lipoprotein. (1985) (21)
Effects of dietary maritime pine seed oil on lipoprotein metabolism and atherosclerosis development in mice expressing human apolipoprotein B (2001) (21)
Cholesterol esters selectively delivered in vivo by high-density-lipoprotein subclass LpA-I to rat liver are processed faster into bile acids than are LpA-I/A-II-derived cholesterol esters. (1993) (21)
Familial defective apolipoprotein B-100 and myocardial infarction. The ECTIM study. Etude Cas-Témoins de l'Infarctus du Myocarde. (1995) (20)
Novel QTLs for HDL levels identified in mice by controlling for Apoa2 allelic effects: confirmation of a chromosome 6 locus in a congenic strain. (2004) (20)
Lipoproteins containing apolipoprotein A-IV: composition and relation to cholesterol esterification. (1994) (20)
Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage. (2008) (20)
Phosphatidylcholine breakdown in HDL3 stimulated platelets. (1990) (20)
Interactions of high-density lipoprotein 3 with brain capillary endothelial cells. (1989) (20)
Chapter 10 Free radicals and atherosclerosis (1994) (20)
Postprandial Dyslipidemia: A Risk Factor for Coronary Heart Disease (1998) (19)
Apolipoprotein E Knockout Mice Over-Expressing Human Tissue Inhibitor of Metalloproteinase 1 Are Protected against Aneurysm Formation but Not against Atherosclerotic Plaque Development (2006) (19)
Identification of Reverb as a physiological repressor of apoC-III gene transcription 1 (2002) (19)
The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. (2000) (19)
Human very low density lipoprotein structure: interaction of the C apolipoproteins with apolipoprotein B-100. (1993) (19)
Glucose regulates the expression of the apolipoprotein A5 gene. (2008) (19)
A 700-bp fragment of the human antithrombin III promoter is sufficient to confer high, tissue-specific expression on human apolipoprotein A-II in transgenic mice. (1995) (19)
Determination of amniotic fluid phospholipids by thin-layer chromatography, with use of a hydrogen flame ionization detector. (1979) (19)
Endothelial derived vasorelaxation is impaired in human APO A-I transgenic rabbits. (1997) (18)
Effects of fenofibrate on lipoprotein metabolism and fatty acid distribution in Zucker rats. (1988) (18)
High-density-lipoprotein subfraction 3 interaction with glycosylphosphatidylinositol-anchored proteins. (1997) (18)
Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia. (2001) (17)
PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis. (2007) (17)
Evidence of non-deficient low-density lipoprotein receptor patients in a pool of subjects with clinical familial hypercholesterolemia profile. (1994) (17)
Effects of dietary maritime pine (Pinus pinaster)-seed oil on high-density lipoprotein levels and in vitro cholesterol efflux in mice expressing human apolipoprotein A-I. (2000) (17)
Is cholesterol the major lipoprotein risk factor in coronary heart disease?--a Franco-Scottish overview. (1997) (17)
Lipoproteins, apolipoproteins and coronary artery disease assessed by coronary arteriography (1982) (17)
Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype. (1997) (17)
Aspects of cholesterol metabolism in normal and hypercholesterolemic Syrian hamsters. Influence of fenofibrate. (1988) (17)
The polymorphism ApoB/4311 in patients with myocardial infarction and controls: the ECTIM study (1992) (16)
Expression and secretion of human apolipoprotein A‐I in the heart (2004) (16)
Lipoprotein(a) as a marker for coronary heart disease. (1994) (16)
Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists. (2004) (16)
Association for the Study of Obesity Heart Federation; International Atherosclerosis Society; and International National Heart, Lung, and Blood Institute; American Heart Association; World International Diabetes Federation Task Force on Epidemiology and Prevention; Harmonizing the Metabolic Syndrome (2009) (16)
Improved serum lipoprotein electrophoresis procedure in polyacrylamide gradient gel. (1975) (16)
Binding characteristics of high density lipoprotein subclasses to porcine liver, adrenal and skeletal muscle plasma membranes. (1989) (15)
Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles. (2000) (15)
Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. (1995) (15)
Apo AIV in plasma and dialysate fluid of CAPD patients: comparison with other apolipoproteins. (1992) (15)
Sequential estrogen-progestin replacement therapy in healthy postmenopausal women: effects on cholesterol efflux capacity and key proteins regulating high-density lipoprotein levels. (2002) (15)
Oxidized High-Density Lipoproteins Modulate Endothelin Secretion by Adult Bovine Aortic Endothelial Cells (1995) (15)
Lipoprotein particle measurement: an alternative approach to classification of lipid disorders (1991) (15)
Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians (2011) (15)
Very-low-density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro. (1996) (15)
Transcription of the human apolipoprotein A-II is down-regulated by the first intron of its gene. (1994) (15)
Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides or triglyceride-rich lipoproteins in humans (2000) (15)
In vivo glucosylated LpA-I subfraction. Evidence for structural and functional alterations. (1997) (15)
Immunochemical determination of human apolipoprotein B by laser nephelometry. (1979) (15)
Pocket guide to prevention of coronary heart disease (2003) (15)
Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture. (2001) (14)
Interstitial fluid apolipoprotein A-II: an association with the occurrence of myocardial infarction. (1996) (14)
Confusion of apolipoprotein E phenotyping by serum amyloid A. (1989) (14)
Recent progress in the study of ApoA-containing lipoprotein particles. (1991) (14)
Increased Susceptibility of Low-Density Lipoprotein to Ex Vivo Oxidation in Mice Transgenic for Human Apolipoprotein B Treated with 1 Melatonin-Related Compound Is Not Associated with Atherosclerosis Progression (2005) (14)
Rapid sodium dodecyl sulfat/polyacrylamide gel electrophoresis of urinary proteins. (1980) (14)
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel? (2021) (14)
Absence of relationship between plasma Lp(a), Lp-AI, anti-oxidized LDL autoantibodies, LDL immune complexes concentrations and restenosis after percutaneous transluminal coronary angioplasty. (2000) (14)
[Focus on the classification of plasma lipoproteins]. (1985) (14)
Apolipoprotein B signal peptide polymorphism in patients with myocardial infarction and controls (2004) (14)
Changes in fatty acid composition of cardiac mitochondrial phospholipids in rats fed rapeseed oil (1978) (13)
Antioxidant activity of pinoline analogues in the LDL oxidation model (2002) (13)
Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene. (1996) (13)
Rat monoclonal antibodies to human apolipoprotein B: advantages and applications. (1989) (13)
Association of synthetic peptide fragments of human apolipoprotein A-I with phospholipids. (1995) (13)
Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group. (1994) (13)
Expression of apolipoprotein B epitopes in low density lipoproteins of hemodialyzed patients. (1993) (13)
The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes (2007) (13)
The plasma and lipoprotein triglyceride postprandial response to a carbohydrate tolerance test differs in lean and massively obese normolipidemic women. (2002) (13)
Complete functional rescue of the ABCA1−/− mouse by human BAC transgenesis Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M400506-JLR200 (2005) (13)
Electroimmuno- and immunonephelometric assays of apolipoprotein A-I by using a mixture of monoclonal antibodies. (1988) (13)
Development of a radial immunodiffusion technique employing monoclonal antibodies for apolipoprotein B determination in human plasma. (1985) (13)
Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CIII and LDL subfractions (2001) (13)
Tangier disease: isolation and characterization of LpA-I, LpA-II, LpA-I: A-II and LpA-IV particles from plasma. (1993) (13)
Different ways to regulate the PPARalpha stability. (2004) (13)
Transcriptional Regulation of Apolipoprotein A5 Gene Expression by theNuclear Receptor ROR alpha (2004) (12)
Drug transfer across the blood-brain barrier: comparison of in vitro and in vivo models. (1993) (12)
Lipid lowering actions of 7-(2-methylene butyryl)-(2H)-1,4-benzoxazin-3-(4H)-one derivatives in mice, rats and Syrian hamsters. (1989) (12)
Serum lipoprotein profile in Algerian patients with celiac disease. (1995) (12)
Sources of variability of human plasma apolipoprotein A‐IV levels and relationships with lipid metabolism (1994) (12)
Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine (2004) (12)
Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cells. (2006) (12)
Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis. (2006) (12)
Evaluation of apolipoprotein A-I containing particles in chronic renal failure patients undergoing hemodialysis. (1990) (12)
Effect of the inflammation, chronic hyperglycemia, or malabsorption on the apolipoprotein A-IV concentration in type 1 diabetes mellitus and in diabetes secondary to chronic pancreatitis. (2001) (12)
Immunological and functional properties of in vitro oxidized low density lipoprotein. (1995) (12)
Effects of unsaturated fatty acids in phospholipids on the in vitro activation of the lipoprotein lipase and the triglyceride lipase. (1979) (12)
Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency Published, JLR Papers in Press, February 23, 2006. (2006) (11)
Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia (1998) (11)
Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. (2004) (11)
Guidelines and their Implementation: A Discussion Document Focused on the Best Approaches to Drive Improvement (2004) (11)
Enzyme-linked immunosorbent assay for serum amyloid A apolipoprotein with use of specific antibodies against synthetic peptides. (1988) (11)
SPPARM alpha: the Lazarus effect. (2019) (11)
Novel peroxisome proliferator activated receptor-alpha agonists. (2007) (11)
Therapeutical effects of PPAR agonists assessed by biomarker modulation (2005) (11)
Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release. (2004) (11)
EUROSTERONE MEETING Peroxisome proliferator-activated receptors in inflammation control (2001) (11)
[Erucic acid metabolism in man and animals: myocardial extraction in man after an overload of rapeseed oil and tissue lipids in the rat after an overload of trierucin]. (1973) (11)
Association between epitopes detected by monoclonal antibody BIP‐45 and the Xbal polymorphism of Apolipoprotein B (1988) (11)
Experimental studies on the regulation of myocardial and adipose tissue lipoprotein lipase activitites in rat. (1974) (11)
A monoclonal antibody (BIP 45) detects Ag(c,g) polymorphism of human apolipoprotein B. (1987) (11)
Automatisation en fluorimetrie du dosage enzymatique du cholesterol total serique (1975) (10)
Non-enzymatic glycosylation of apolipoprotein A-I and its functional consequences. (1995) (10)
Effect of different APO A-I containing lipoprotein particles on reverse cholesterol transport in fat cells. (1988) (10)
CYS127S (FH-Kairouan) and D245N (FH-Tozeur) mutations in the LDL receptor gene in Tunisian families with familial hypercholesterolaemia (2002) (10)
[4‐(2H‐1,2,3‐Benzotriazol‐2‐yl)phenoxy]alkanoic Acids as Agonists of Peroxisome Proliferator‐Activated Receptors (PPARs) (2006) (10)
HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. (2002) (10)
HDL3 binds to glycosylphosphatidylinositol-anchored proteins to activate signalling pathways. (1997) (10)
The blood-brain barrier in vitro : co-culture of brain capillary endothelial cells and astrocytes (1990) (10)
Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders. (2007) (10)
Human apolipoprotein B. Evidence for its immunochemical heterogeneity using monoclonal antibodies and an immunoenzymometric assay. (1988) (10)
Letter to the editorFamilial defective apolipoprotein B-100 and myocardial infarction. The ECTIM study (1995) (9)
Peroxisome Proliferator-Activated Receptor β/δ: A novel target for the reduction of atherosclerosis (2005) (9)
Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia (2004) (9)
The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein (a) levels in familial hypercholesterolemia. (1996) (9)
Changes in rat heart phospholipid composition after rapeseed oil feeding (1977) (9)
Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group. (1994) (9)
Preparation of anti-HIV-low-density lipoprotein complexes for delivery of anti-HIV drugs via the low-density lipoprotein pathways. (1994) (9)
Peroxisome Proliferator–Activated Receptor (cid:1) Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR- (cid:1) Activation Properties (2004) (9)
Postprandial lipaemia is associated with increased levels of apolipoprotein A-IV in the triacylglycerol-rich fraction and decreased levels in the denser plasma fractions (1997) (9)
Apolipoprotein A-V Modulates Insulin Secretion in Pancreatic β-cells Through its Interaction with Midkine (2009) (9)
HDL particle measurements: impact for diagnosis and therapy. (1993) (9)
HDL3-signalling in HepG2 cells involves glycosyl-phosphatidylinositol-anchored proteins. (1997) (9)
Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene. (2006) (9)
Recent developments in the treatment of hypertriglyceridemia (1999) (9)
Effects of fenofibrate on apolipoprotein B-containing particles in patients with hyperlipoproteinemia (1990) (8)
Dosage semi-automatique de l'activité lipolytique du plasma post-héparine. Bilan des premiéres applications cliniques (1972) (8)
Evolution Pattern of Auto-Antibodies against Oxidized Low-Density Lipoproteins in Renal Transplant Recipients (2001) (8)
Fenofibric acid modulates the human apolipoprotein A-IV gene expression in HepG2 cells. (1994) (8)
Variations in Apolipoproteins Serum Amyloid A, A-I, A-II, and C-III in Severely Head-Injured Patients (1990) (8)
Apolipoprotein AI and apolipoprotein B containing particle analysis in normolipidemic hemodialyzed patients: evidence of free apolipoprotein E. (1996) (8)
Plasma Removal of Intravenous Essential Phospholipids in Man (1976) (8)
Insulin-resistance and lipoprotein abnormalities. (1991) (8)
The role of a triplet repeat sequence of the very low density lipoprotein receptor gene in plasma lipid and lipoprotein level variability in humans. (1997) (8)
Accessibility of human apolipoprotein B-100 epitopes in insulin-dependent diabetes: relation with the surface lipid environment of atherogenic particles. (1996) (8)
A phenocopy of type III dysbetalipoproteinemia occurring in a candidate family for a putative apo E receptor defect. (1991) (7)
Inhibition enzyme immunoassay, application to human apolipoprotein B. (1978) (7)
Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i) (2014) (7)
Lipoprotein heterogeneity and its effect on apolipoprotein assays. (1990) (7)
Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients. (1996) (7)
Antipeptide antibodies discriminate between different SAA proteins in human plasma. (1989) (7)
Synthetic peptides as alternative antigens in the production of antibodies against human apolipoproteins. (1985) (7)
Comparison of maritime pine oil and fish oil effects on plasma lipoproteins in apolipoprotein E-deficient mice. (2000) (7)
Lipoproteins, apolipoproteins and coronary artery disease (1982) (7)
Oxidized low density lipoproteins exert arrhythmogenic effects in rabbit Purkinje fibers. (1992) (7)
Pharmacomodulation of 7-(2-methylene-butyryl)-2,3-dihydrobenzoxazin-[1,4]-3-one structure and normolipemic activity. (1991) (7)
Lipoprotein receptors. (1994) (7)
Immunochemical characterization of two antigenic sites on human apolipoprotein A-I; localization and lipid modulation of these epitopes. (1988) (7)
A screening method for abnormally high lipoprotein(a) concentrations by agarose lipoprotein electrophoresis. (1994) (7)
Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease? (2020) (7)
Branched synthetic constructs that mimic the physico-chemical properties of apolipoprotein AI in reconstituted high-density lipoproteins. (1996) (7)
[Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development]. (2003) (7)
Oxidised LDL Modulates Endothelin Secretion by Adult Bovine Aortic Endothelial Cells (1995) (6)
Modulation of the expression of human LDL-Apo B-100 epitopes by lipids and apolipoproteins. (1993) (6)
Electroimmunoassay for determination of ApoB in human sera by using a mixture of monoclonal antibodies. (1987) (6)
Apolipoprotein B polymorphism and altered apolipoprotein B concentrations in Congolese blacks (1991) (6)
[Reverse cholesterol transport and use of transgenic mice and rabbits to reveal candidate genes for protection against atherosclerosis]. (1998) (6)
Alteration of the lipid and apolipoprotein contents of lipoprotein (a) in haemodialysis patients. (1996) (6)
[Interaction between LDL receptor and lipoproteins containing apo B]. (1991) (6)
Ppar-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis (2003) (6)
Depletion in choline containing phospholipids of LpB particles in adequately controlled type I insulin-dependent diabetes mellitus. (1990) (6)
Changes in plasmaapolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine (1995) (6)
Lipoprotein A-I containing particles. (1991) (6)
[Effect of alcohol on removal of lipids from plasma after hyperlipemic induced by a fatty meal or perfusion of lipid emulsions in man]. (1973) (6)
Adipose tissue lipoprotein lipase activity in Plasmodium chabaudi and Plasmodium vinckei rodent malaria. (1982) (6)
[Lipids, lipoproteins and atherosclerosis]. (1991) (6)
Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes. (1996) (6)
HMG CoA reductase inhibitors and PPAR-α activators: Are their effects on high-density lipoprotein cholesterol and their pleiotropic effects clinically relevant in prevention trials? (2002) (6)
Lipoprotein particles in homozygous familial hypercholesterolemic patients treated with portacaval shunt and LDL apheresis. (1990) (5)
3P-0816∗ Apolipoprotein A5 is an inflammatory responsive gene down-regulated by tumor necrosis factorα and interleukin-1 (2003) (5)
[Anti-cholesterol agents, new therapeutic approaches]. (2004) (5)
PL05 Mechanism of action of fibrates on lipid and lipoprotein metabolism (1998) (5)
PPARs and Atherosclerosis (2000) (5)
Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia (2004) (5)
HDL receptor and reverse cholesterol transport in adipose cells. (1988) (5)
Upregulation of the low density lipoprotein receptor at the blood-brain barrier: Intercommunications between brain capillary ECs and astrocytes. J. Cell Biol. 126:465-474 (1994) (5)
Lipoproteins and Reconstituted Blood-Brain Barrier (1991) (5)
[PPAR gamma: a major nuclear receptor in adipogenesis]. (2003) (5)
Apolipoprotein B immunochemical heterogeneity in dialysed patients with chronic renal failure and patients with coronary artery stenosis. (1989) (5)
Serum Lp AI lipoprotein particles and other antiatherogenic lipid parameters in normolipidaemic obese subjects. (1996) (5)
[Modified lipoproteins and atherogenesis]. (1989) (5)
Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis (2022) (5)
Location of Probucol in Lipoproteins Inferred from Compositional Analysis of Lipoprotein Particles. An In‐vitro Study (1994) (5)
On-treatment Levels of HDL-C and the Ratio of LDL-C/HDL-C as Predictors of Cardiovascular Events in the Treating to New Targets (TNT) Study (2006) (5)
Neutral-lipid transfers and cholesteryl ester transfer protein in hemodialyzed patients. (1996) (5)
Distribution of lipid variables in subjects in Belfast, Northern Ireland and Taiyuan, P R China. (1993) (4)
Changes in lipoproteins induced by the remnant kidney tissue or binephrectomy in chronic uremic patients treated by hemodialysis. (1989) (4)
Apolipoprotein A5 is an inflammatory responsive gene down-regulated by tumor necrosis factor alpha and interleukin-1 (2004) (4)
Branched synthetic peptide constructs mimic cellular binding and efflux of apolipoprotein AI in reconstituted high density lipoproteins. (1998) (4)
PCSK9: The functional relevance of fenofibrate–statin combination therapy to reduce residual cardiovascular risk (2015) (4)
Leptin response to carbohydrate or fat meal and association with subsequent satiety and energy intake. (1999) (4)
[Dyslipoproteinemia of the Lla Type - Effects of Simvastatine and Bezafibrate On Atherogenic and Nonatherogenic Lipoproteic Particles] (1988) (4)
[Clinical and experimental study of modifications in plasma lipids induced by alcohol]. (1971) (4)
Structure determination of the polymorphism of acylgalactosylceramide in rat brain by gas chromatography/mass spectrometry and proton magnetic resonance. (1987) (4)
Determination precise du rapport lecithine/sphingomyeline dans le liquide amniotique: Proposition d'une methode de reference. (1977) (4)
Relationship between low‐density lipoprotein size and apolipoprotein A‐I‐containing particles: the ECTIM study (1997) (4)
HDL metabolic activities in a boy with lipoprotein lipase deficiency and his family (2004) (4)
[Fundamental data on atherosclerosis]. (2001) (4)
[Plasma lipoproteins and apolipoproteins. Value of their determination in the detection of coronary atherosclerosis. Comparison with data supplied by coronarography]. (1982) (4)
The science behind statins and fibrates. (2002) (4)
Metabolism of lipoproteins in rodent malaria, relationship between lipolysis, steatosis and increased biosynthesis of V.L.D.L. (1981) (4)
Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group. (1995) (3)
[PPARs activators and regulation of lipid metabolism, vascular inflammation and atherosclerosis]. (2001) (3)
PO2-33 THE INCREASE OF APOA-V DURING POSTPRANDIAL LIPEMIA FOLLOWS THE RESPONSE OF TRIGLYCERIDE-RICH LIPOPROTEINS (TRL) IN TYPE 2 DIABETES (2007) (3)
W11.280 Ciprofibrate increases synthesis and catabolism of HDL apo AI and AII in patients with hyperlipidemia (2004) (3)
132 Protective effect of human apo A-II overexpression on atherogenesis in transgenic mice (1997) (3)
Apolipoprotein-AI-containing particles and atherosclerosis. (1996) (3)
Lack of relationship between Lp(a) particle levels and albumin excretion rate in type 1 diabetic patients. (1994) (3)
Fractionation of serum lipoproteins by preparative electrophoresis in polyacrylamide gel. (1977) (3)
PPARs in Atherosclerosis (2006) (3)
Apolipoprotein A 5 , a Crucial Determinant of Plasma Triglyceride Levels , is Highly Responsive to PPAR α Activators (2003) (3)
Post-statin approaches to hyperlipidaemia. (1998) (3)
Triglyceride-rich particles, high-density lipoprotein and their pharmacological modulation. (1993) (3)
[The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome]. (2011) (3)
Lipoprotein metabolism during experimental rodent malaria. (1980) (3)
[Lipoprotein (a). An additional marker of atherosclerosis]. (1990) (3)
Quantitation of human serum apolipoprotein B by enzyme immunoassay in excess antigen. (1986) (3)
0.S.8 Mechanisms of the hypolipidemic action of fibrates (1997) (3)
Effect of Fenofibrate on Lipoprotein Particles Predictive of Coronary Atherosclerosis (1987) (3)
Involvement of intronic sequences in the transcriptional regulation of apolipoprotein B, E and A-II genes. (1996) (3)
Apolipoprotein E-epsilon 4 allele and Alzheimer's disease. (1993) (3)
Atherosclerosis XI : proceedings of the XIth International Symposium on Atherosclerosis, held in Paris, France, on 5-9 October 1997 (1998) (3)
[Metabolic study of 3 lipid emulsions used parenteral feedings. I. Exploration in vivo in the minipig]. (1975) (3)
PPAR activators improve glucose homeostasis by changing fatty acid partitioning (1998) (3)
Normolipemic activities of acrylophenone derivatives with antimicrotubular properties. (1985) (3)
91 Δ5 olefinic acids extracted from pine tree seeds decrease serum triglyceride levels in rats (1997) (3)
Regulation of macrophage lipoprotein lipase expression by activators of peroxisome proliferator-activated receptors* (1999) (2)
Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists (2005) (2)
[PPAR receptors at the crossroads of obesity, diabetes and cardiovascular diseases]. (2007) (2)
Angiogenin Acts as a Direct Mitogen on Bovine Brain Capillary Endothelial Cells (1991) (2)
Antibodies of predetermined specificity to apolipoprotein C-II elicited with a synthetic peptide. Characterization and use for immunoassays. (1988) (2)
[Semi-automatic colorimetric determination of fatty acids. Applications: determination of plasma free fatty acids, serum lipase and post-heparin plasma triglyceride-lipases]. (1974) (2)
1.P.194 Thiazolidinediones exert a hypotriglyceridemic effect by a distinct, but complementary mechanism relative to fibrates (1997) (2)
Fish eye disease: structural and metabolic abnormalities of high density lipoproteins (1994) (2)
Antipeptide antibody against the human low-density-lipoprotein receptor. Characterization and cross-reactivity with bovine lymphocytes. (1989) (2)
[New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis]. (2001) (2)
[Use of polyunsaturated phospholipids in the treatment of fat embolism]. (1974) (2)
Regulation of CLA-1 (CD36 and limp II analogous I) by activators of peroxisome proliferator activated receptors (PPARS) (1999) (2)
Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key? (2019) (2)
[Receptors and molecular heterogeneity of lipoprotein particles containing apolipoprotein A-I]. (1988) (2)
[The important role of apolipoprotein C-III in lipoprotein metabolism]. (1995) (2)
Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications (2002) (2)
[Vitamin E, antioxidants and atherosclerosis]. (1994) (2)
[From cholesterol to lipoprotein particle markers and/or risk factors]. (1991) (2)
Apolipoprotein B measurement in blood spotted on paper (1982) (2)
Binding of apolipoproteins A to adipose cells: role of receptor sites in cholesterol efflux and purification of binding protein(s). (1991) (2)
Tissue-specific down-regulation of apo C-III gene expression by fibrates (1994) (2)
Are nuclear factors the ultimate targets of drugs affecting lipid metabolism? (2000) (2)
[Changes in the cholesterol levels of high density lipoproteins following the intravenous administration of triton WR 1339 to rats (author's transl)]. (1980) (2)
1.P.95 Effects of Δ5-olefinic acids from Pinus pinaster seed oil on lipoprotein metabolism in apoE deficient mice (1997) (2)
Measurement of lipoprotein particles. (1998) (2)
Quantitative abnormalities of lipoprotein particles in chronic hemodialysis patients. (1988) (2)
10. HDL subclasses impact of metabolic and therapeutic interventions (1999) (1)
S38 HDL, reverse cholesterol transport and atherogenesis (1998) (1)
[Atherogenic lipoproteins and their immunological detection]. (1985) (1)
Inter-Communication Between Brain Capillary Endothelial Cells and Astrocytes: Upregulation of the LDL Receptor at the Blood-Brained Barrier (1993) (1)
Plasmapheresis in type IIa hypercholesterolaemia (1982) (1)
Chapter 1. Lipoproteins in Health and Disease: Lipoprotein Nomenclature and the Classification of Hyperlipoproteinemia (1989) (1)
Estrogen-progestin replacement therapy raises Lp A-i particles, HDL lipids and cholesterol efflux from Fu5AH cells (2000) (1)
Heterozygous lipoprotein lipase (LPL) deficiency: lipid and apolipoprotein composition of lipoproteins suggest increased risk for coronary heart disease (1994) (1)
P eroxisome Proliferator-Activated Receptors at the rossroads of Obesity , Diabetes , and Cardiovascular Disease (2006) (1)
[Effect of clofibrate on tissue lipase activity in rats]. (1976) (1)
Prevention of coronary heart disease in post-menopausal women. (2000) (1)
[Lipoprotein electrophoresis on acrylamide-agarose plates, with discontinuous acrylamide gradient]. (1979) (1)
High-density lipoprotein particles, nutrition and arteriosclerosis. (1992) (1)
Th-W60:3 Acute anti-inflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the PKC signalling pathway (2006) (1)
144 Overexpression of human apolipoprotein A-I in transgenic rabbits (1997) (1)
[Metabolic study of 3 fat emulsions for intravenous nutrition. II. Study by isolated rat liver perfusion]. (1975) (1)
[Application of polyacrylamide gel electrophoresis-SDS to the study of proteinuria (author's transl)]. (1978) (1)
4.P.348 Caveolae and glycosyl phosphatidylinositol-anchored proteins: A specific binding membrane domain for high density lipoproteins (1997) (1)
Risk factors in two populations at contrasting risk for coronary artery disease (1998) (1)
[Automation of fluorometric enzymatic determination of free and total cholesterol. Application to the determination of the esterification rate]. (1975) (1)
[Serum amyloid A apolipoprotein (apo SAA). Implications in inflammation and in lipoprotein modifications]. (1990) (1)
[Detection of a new lipoprotein: Lp(a). Its occurrence in atherosclerosis with or without hyperlipemia]. (1977) (1)
[Influence of alcohol on plasma lipids and atherogenesis. Epidemiological and biochemical aspects]. (1991) (1)
[Diagnosis of jaundice caused by obstruction of the extra-hepatic bile ducts. Study of Au serum lipids and lipoproteins]. (1973) (1)
Phosphorylation-dependent down-regulation of apolipoprotein A5 by insulin (2004) (1)
[Statins for cardiovascular prevention. Lowering LDL cholesterol, the primary objective]. (2002) (1)
Peroxisome proliferator-activated receptor α controls cellular cholesterol trafficking in macrophages Published, JLR Papers in Press, September 14, 2005. DOI 10.1194/jlr.M500326-JLR200 (2005) (1)
3.P.112 Differential effects of air (mO-LDL) or copper oxidized LDLs (Cu-LDL) on endothelial cell GSH content (1997) (1)
The effect of diet on lipid, apoprotein and lipoparticle variation in the ECTIM study in Belfast. (1995) (1)
Expression, location and cross-reactivity of two antigenic sites on the amino terminal region of rabbit and human apolipoprotein A-I. (1989) (1)
Evaluation of a method for quantitative serum lipoprotein analysis (1982) (1)
Apolipoproteins in human amniotic fluid: concentrations, isoforms and polymorphism. (1989) (1)
PPAR-α and atherosclerosis from basic research to clinical applications (2004) (1)
Nondiabetic Mouse Model of Mixed Dyslipidemia , Activators Decrease Macrophage-Laden Atherosclerotic Lesions (2005) (1)
Plasma lipids and lipoproteins in the grass-cutter, thryonomys swznderianus, in captivity' (1996) (1)
[Alcohol-induced hyperlipemia: possible role of an error of plasma lipid purification]. (1973) (1)
W15-O-003 Atheroprotective effect of the rexinoid targretin in a murine model of atherosclerosis (2005) (1)
Molecular analysis of atherogenic lipoprotein particles in adequately controlled type I diabetes mellitus. (1988) (1)
Effect of fenofibrate on apolipoprotein B containing lipoprotein particles. (1988) (1)
1.P.395 Measurements of VLDL-, IDL-, and LDL-apo B levels by a combination of isopropanol precipitation and mass spectrometry (1997) (1)
Scavenger Receptor but Inhibits Specific Cholesteryl Ester Uptake Apolipoprotein AII Enrichment of HDL Enhances Their Affinity for Class B Type I (2000) (1)
Leptin, a Pleiotropic Hormone: Physiology, Pharmacology, and Strategies for Discovery of Leptin Modulators (1999) (1)
Measurement of rabbit apolipoprotein B by use of electroimmunodiffusion and immunonephelometric assays. (2000) (1)
Tu-P7:140 Paullina pinnata extracts rich in polyphenol promote vascular relaxation via endothelium-dependent mechanisms (2006) (1)
[Genes, dyslipoproteinemias and atherosclerosis: from the experimental to the therapeutic]. (1999) (1)
Mapping of lipoprotein particles with monoclonal antibodies in diabetes and atherosclerosis. (1985) (1)
Native like structure and stability of apo AI in a n‐propanol/water solution as determined by 13C NMR (1995) (1)
Bile acids suppress human apolipoprotein A-I gene expression via a negative response element for the nuclear receptor FXR (2001) (1)
ROLE OF PPARs IN INFLAMMATION, ATHEROSCLEROSIS, AND THROMBOSIS (2002) (1)
Fibrates, Sequestrant Resines and HMG CoA Reductase Inhibitors and Lipoprotein Particles (1989) (1)
Abstract: 1520 THE RESIDUAL RISK REDUCTION INITIATIVE (R3I): ADDRESSING A MAJOR CHALLENGE FOR HEALTHCARE (2009) (1)
Role of the nuclear orphan receptor Rev-erb??; in the regulation of bile acid synthesis (2006) (1)
Vaccine for treatment of atherosclerosis (2001) (1)
[New methods in lipid research]. (1994) (1)
[Detection of the Arg 3500-->Gln mutation of B apolipoprotein. Value in clinical practice]. (1995) (1)
Chemical approach to synthetic immunogens in clinical chemistry. (1987) (1)
[Determination of blood salicylate levels in humans after intravenous and intramuscular administration of lysine acetylsalicylate]. (1975) (1)
Molecular analysis of lipoproteins — clinical application (1992) (0)
4.P.90 Oxidative stress in diabetes secondary to chronic pancreatitis (1997) (0)
Independent effects of apolipoprotein AV and apolipoprotein CIII on plasma triglyceride concentrations (2003) (0)
[Serum lipase assay for clinical use. Critical study (author's transl)]. (1980) (0)
[Liaison of apolipoprotein A with adipose cells: characteristics of the receptor sites and their role in the efflux of cholesterol]. (1991) (0)
Mo-PL1:2 The PPAR alpha system: A prototype of nuclear receptor (2006) (0)
Apo A-I Containing Particles and Atherosclerosis (1995) (0)
Apolipoprotein AI containing HDL particles in CHD patients and their children (1995) (0)
Fasting plasma insulin is an independent predictor of cardiac events at one year after percutaneous coronary revascularization (2003) (0)
1.P.76 Evolution of immunological markers of LDL oxidation in cholesterol-fed human apolipoprotein AI transgenic rabbits (1997) (0)
147 Metabolic role of apolipoprotein A-II studies in transgenic mice (1997) (0)
[Hyperlipemia in chronic kidney failure]. (1979) (0)
Response of leptin levels to short term feeding and fasting in man, influence of circadian cycle (1998) (0)
[Determination of lipoprotein lipase activity in adipose tissue in humans and animals]. (1973) (0)
[Exact determination of the lecithin/sphingomyelin ratio in amniotic fluid. Suggestion of a reference methods (author's transl)]. (1977) (0)
[Hyperlipoproteinemia. I. Application, apropos of 133 cases, of clinical and biochemical criteria of the classification of hyperproteinemias]. (1972) (0)
Paraoxonase activity in primary hypertriglyceridemia (2000) (0)
Triglycerides and Risk for Atherosclerotic Disease (2006) (0)
Book Review – Buchbesprechung – Livre nouveau / Varia (1973) (0)
Decrease in cholesteryl ester transfer protein (CETP) activity and mass in chronic hemodialysed women (1994) (0)
Apolipoprotein B: Immunological Methods for the Detection of Mutants (1989) (0)
[Semi-automatic determination of post-heparin plasma lipolytic activity. Clinical studies]. (1972) (0)
Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content (2020) (0)
Biochemical and Molecular Action of Nutrients Pinus pinaster Oil Affects Lipoprotein Metabolism in Apolipoprotein E-Deficient Mice 1 (1999) (0)
Quantitative and qualitative variations of plasma non-esterified fatty acids in normal persons after a load of lipid given by mouth. (1971) (0)
Indications and Clinical Use of Fibrates in Specific Lipoprotein Disorders Primary Hypertriglyceridemia (1998) (0)
Subject Index, Vol. 19, 1975 (1975) (0)
4.P.200 Fat ingestion is associated with increased levels of apoC-III-and apoE-B-containing particles in human (1997) (0)
A pedigree with a large deletion in the LDL receptor gene and unexpected lipid levels: Association with specific DNA haplotype (1990) (0)
[Study by preparative ultracentrifugation of the lipid composition of the main classes of plasma lipoproteins in normal subjects and in atherosclerosis without manifest hyperlipemia state]. (1970) (0)
[Use of 6 serum pools in standardization of the determination of apolipoproteins AI and B in the human serum]. (1990) (0)
[Clinical value of the lipidogram on polyacrylamide gel in gradient densityin dyslopemia tests]. (1974) (0)
Apo A-I containing particles and reverse cholesterol transport (1994) (0)
3P-0818 GFT14, a novel compound with hypolipidemic and neuroprotective properties (2003) (0)
3P-0818 GFT14, a novel compound with hypolipidemic and neuroprotective properties (2003) (0)
Intercommunication between brain capillary endothelial cells and astrocytes: Upregulation of the LDL receptor at the BBB (1992) (0)
[Fatty acid composition of the steroids of the main classes of beta-lipoproteins isolated by ultracentrifugation in normal and hyperglyceridemic subjects with or without associated atheroma]. (1972) (0)
Characterization of Lipoprotein Particles Containing Apolipoprotein A-IV (1993) (0)
An InternationalCollaborativeStudyon Standardizationof ApolipoproteinsA-I and B. Part I. Evaluationof a LyophilizedCandidateReferenceand CalibrationMaterial1 (1987) (0)
PPARs regulate genes involved in cholesterol homeostasis in human monocyte/macrophages (2000) (0)
PPAR-ALPHA deficiency aggravates diabetes in ob/ob mice (2005) (0)
[Relative concentration of VLDL C-apolipoproteins in the hyperlipoproteinaemia of haemodialysis-treated chronic renal failure (author's transl)]. (1980) (0)
Determination of AmnioticFluidPhospholipids byThin-Layer Chromatography, withUseof a Hydrogen FlameIonization Detector (1979) (0)
PPAR&agr; Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages (2001) (0)
[Molecular analysis of atherogenic and protective lipoproteins]. (1987) (0)
Structure and promoter analysis of the human PPARa gene (2000) (0)
[Conformational changes in lipoproteins containing apo B: significance of monoclonal antibodies]. (1991) (0)
[Amniotic fluid phospholipids and fetal maturity (proceedings)]. (1978) (0)
of lipoparticle AI in adolescents Parental history of early myocardial infarction is associated with decreased levels (2011) (0)
[Rapid disappearance of a non-myelomatous IgG type dysglobulinemia during treatment with a synthetic corticostimuline]. (1970) (0)
[Characterization of the lipoprotein lipase of rat adipose tissue]. (1974) (0)
1.P.181 Effects of fish oil (MAXEPA) on atherogenic lipoprotein particles defined by apolipoprotein composition (LpE: B, LpC-III:B) in patients with mixed hyperlipidemia (1997) (0)
Influence of meal time on postprandial lipemia (1996) (0)
Contents, Vol. 59, 1991 (1991) (0)
[Purification and partial characterization of lipoprotein Lp (a)]. (1977) (0)
Structure-Function Relationships of Apolipoprotein A-I Variants (1993) (0)
Contents, Vol. 19, 1975 (1975) (0)
Abstract 261: Dissociation of Anti-inflammatory from Normolipemic Properties of PPARalpha (2006) (0)
Coronary Heart Disease: Reducing The Risk A Worldwide View Current Perspective (1999) (0)
[Comparative study of various manual and automatic methods of determination of blood cholesterol]. (1975) (0)
patients The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic (2011) (0)
Tu-P7:228 Thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in macrophages (2006) (0)
[Adipocyte size in primary hypertriglyceridemia with and without obesity (author's transl)]. (1978) (0)
Annual Meeting of the German Society for Microcirculation and Vascular Biology. Munich, Germany, October 12–14, 2006 (2006) (0)
VascularSMCproliferationisacrucialeventinocclusivecardiovasculardiseases.PPARαisanuclearrecep- torcontrollinglipidmetabolismandinflammation,butitsroleintheregulationofSMCgrowthremains tobeestablished.Here,weshowthatPPARα controlsSMCcell-cycleprogressionattheG 1 /Stransitionby (2005) (0)
40 Moderate alcohol consumption in healthy volunteers reduced plasma clearance of apolipoprotein A-II (1997) (0)
[Plasma transport and fate of chylomicrons and VLDL in normal humans]. (1978) (0)
[Regulation of blood cholesterol, mechanism of hypercholesterolemia]. (1989) (0)
Clinical significance of apolipoprotein B containing lipoprotein particles (1990) (0)
Clinical Significance of Lipoprotein Particles (1989) (0)
[Perturbations of lipid metabolism during fat embolism]. (1974) (0)
1.P.90 Protective effect of human apo AI overexpression on atherogenesis in transgenic rabbit (1997) (0)
Analysis of Lipoprotein Particles Using Immunoaffinity Chromatography and ELISA Techniques (1989) (0)
Incorporation of lipophilic prodrugs of ametantrone and mitoxantrone inside low density lipoproteins (LDL) and selective uptake of the prodrug LDL complex via the receptor pathway (1993) (0)
SixDNA polymorphisms inthelowdensity lipoprotein receptor gene:theirgenetic relationship andan example oftheir usefor identifying affected relatives ofpatients with familial hypercholesterolaemia (2011) (0)
2P-0529 A novel family of compounds with beneficial effects in mouse models of dyslipidemia and ischemic stroke (2003) (0)
Fibrates and glitazones stimulate their inactivation through PPAR-dependent up-regulation of the drug metabolizing UGT1A9 enzyme (2003) (0)
2P-0529 A novel family of compounds with beneficial effects in mouse models of dyslipidemia and ischemic stroke (2003) (0)
nzyme-Linked ImmunosorbentAssay for Serum Amyloid A Apolipoproteinwith Use of Specific ntibodiesagainst Synthetic Peptides (1988) (0)
Localisation of SR-BI in caveolae is not required for cholesteryl esters selective uptake in NCI H295R adrenal cell line (1999) (0)
Use of synthetic peptides for specific assays of proproteins: Assay of proapolipoprotein A-I (1988) (0)
1.P.75 Paraoxonase activity in human apolipoprotein A-I transgenic rabbits (1997) (0)
[Studies of lipoprotein lipase activity and adipocyte characteristics in the human: effect of obesity and diabetes (author's transl)]. (1976) (0)
Localisation of SR-BI in caveolae is not required for cholesteryl esters selective uptake in NCI H295R adrenal cell line (1999) (0)
Nuclear receptors in atherosclerosis (2004) (0)
Proposition d'un coefficient unique pour l'évaluation des performances analytiques en biologie clinique (1984) (0)
[Changes in blood lipoproteins during the initial phase of fat embolism. Preliminary study]. (1973) (0)
Connection between cholesterol efflux and atherosclerosis (1995) (0)
Overview. PPAR and cardiovascular risk. (2001) (0)
[Lipoproteins containing apolipoprotein A-I and reverse transport of cholesterol]. (1994) (0)
[Hyperlipoproteineia. II. Dietetic and drug therapy]. (1973) (0)
Method of preparing a lipoprotein modified by the incorporation of a lipophilic active substance, thus obtained modified lipoprotein and pharmaceutical or cosmetic composition containing it. (1990) (0)
Is cholesterol the major lipoprotein C. J. Packard? risk factor in coronary heart disease? - a Franco-Scottish overview (1997) (0)
W15-P-003 Thioredoxin 1 and vitamin D3 upregulated protein 1 (VDUPI), its natural inhibitor, are differentially regulated by PPAR agonists in human macrophages (2005) (0)
W12-O-001 Extracellular human recombinant thioredoxin 1 exerts anti-inflammatory properties on human macrophages (2005) (0)
[Action of rubidomycin on plasma and tissue lipids in rabbits]. (1971) (0)
[Low and very low density lipoproteins. Turbidimetric estimation and clinical applications]. (1976) (0)
Expression in Vascular Cells Peroxisome Proliferator-Activated Receptors and Atherogenesis : Regulators of Gene (2004) (0)
Mechanism of lipid lowering in mice expressing human apolipoprotein A5 (2005) (0)
Postprandial variation of plasma apolipoprotein A-IV SI associated with increased levels in triglycerides-rich fraction (1995) (0)
Interaction Of Atherogenic (VLdL; LdL) And Non Atherogenic Lipoproteins (HDL) With Heparin Fractions Of Various Molecular Size (1981) (0)
EFFECTS OF A FIXED COMBINATION OF FENOFIBRATE AND PRAVASTATIN ON APOLIPOPROTEINS IN HIGH RISK PATIENTS WITH MIXED HYPERLIPIDEMIA (2008) (0)
1.P.16 Enzyme-linked immunosorbent assay for apolipoprotein E in mice serum (1997) (0)
Antiatherogenic Effect of Apolipoprotein A-I Containing Lipoproteins (1989) (0)
[Multivariate analysis of biological markers of excessive consumption of alcohol. Value of lipoprotein parameters]. (1987) (0)
[Serum lipids and lipoproteins in a population from Oran. Comparison with a population from Lille]. (1997) (0)
Effect of Pravastatin on Angiographic Restenosis After Coronary Balloon Angioplasty fn1fn1This study was supported by a grant from Bristol Myers Squibb Laboratories, Paris. (1997) (0)
[Apropos of a case of Refsum's disease: biochemical study]. (1971) (0)
58 Effect of smoking cessation on lipoprotein A-I and lipoprotein A-l:A-II levels (1997) (0)
Is lipoprotein(a) a clinically meaningful risk marker for cardiovascular events in healthy women? (2007) (0)
[Bioclinical importance of blood ferritin determination]. (1981) (0)
3P-0834 Transcriptional regulation of the apolipoprotein A5 gene by insulin (2003) (0)
Influence of Oral and Percutaneous Estrogen Therapy on the Lipoprotein Particle Profile of Postmenopausal Women (1993) (0)
[Determination of lipoproteins defined following their apolipoprotein composition for the prediction of cardiovascular risk]. (1994) (0)
[Clearance of lipid emulsions used in parenteral feeding: study by perfusion of the isolated rat liver and in vivo exploration in the minipig]. (1975) (0)
[Methods for analyzing lipoproteins]. (1986) (0)
A process for producing a modified by incorporation of a lipophilic active substance lipoproteins (1991) (0)
[Application of the immunoenzyme technic in double determination of antibodies for the study of hyperlipoproteinemia]. (1990) (0)
[IgA-transferrin ratio in cirrhosis. Diagnostic and pronostic significance]. (1974) (0)
Mélange d'anticorps monoclonaux anti-apolipoprotéine A-I. Application en electroimmunodiffusion et immunonephelémétrie (1988) (0)
Changes in coronary heart disease risk factors associated with menopause, and influence of substitutive hormone therapy (1994) (0)
Quantitation of human lipoprotein(a) by a new sensitive method: latex immunoassay (1986) (0)
Lipoprotein Particles Heterogeneity: Clinical and Pharmacological Implication (1993) (0)
W15-P-005 Regulation of genes encoding intestinal cholesterol transporters by nuclear receptors in human CACO-2/TC7 enterocytes (2005) (0)
[Cholesterol, lipoproteins and risk factors in atherosclerosis]. (1986) (0)
Aggressive lipid lowering with atorvastatin reduces increased risk of cardiovascular events in patients with metabolic syndrome and coronary heart disease (2006) (0)
Peroxisome proliferator activated receptors and stroke (2003) (0)
[Lipoparticles and atherosclerosis]. (1995) (0)
W08.196 Role of adipophilin on lipid accumulation in human macrophages (2004) (0)
[Lipid composition of circulating lipoproteins in various types of hyperlipoproteinemia (author's transl)]. (1977) (0)
WO2-OR-3 PLASMA APOA5 INCREASESWITH PLASMA TRIGLYCERIDES INDEPENDENTLY FROM LIPOPROTEIN LIPASE ACTIVITY IN HUMAN (2007) (0)
[Methods for the study of proteinuria. Interpretation]. (1983) (0)
[Semi-automatic determination of tissue lipoprotein lipase in man and animals]. (1973) (0)
Heterogeneity of apo A-I- and apo B-containing lipoproteins in children from families with positive CHD history (1994) (0)
Contents Vol. 43, 2006 (2006) (0)
PPARα, Lipoprotein Metabolism, Metabolic Diseases, and Atherosclerosis (2002) (0)
Activity of the lipoprotein lipase in adipose tissue during experimental malaria in rodents. (1980) (0)
[Determination of blood profile of atherogenic lipids using immunologic techniques]. (1990) (0)
Peroxisome Proliferator-Activated Receptor Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective (2005) (0)
Results PPAR Mediates the Acute Antiinflammatory Action of Simvastatin In Vivo (1996) (0)
[Diagnosis of type III hyperlipoproteinemia: contribution of an air-driven ultracentrifuge associated with an original tube-slicer (author's transl]. (1979) (0)
Variations in lipoproteins during aminoglutethimide therapy (1987) (0)
WorkshopW08.196 Role of adipophilin on lipid accumulation in human macrophages (2004) (0)
Cholesterol homeostasis is controlled by peroxisome proliferator-activated receptor alpha in human macrophages (2001) (0)
W15-P-004 PPAR-alpha deficiency aggravates diabetes in OB/OB mice (2005) (0)
Possible role of SREBP1c in fish oil-mediated regulation of APOC-III gene expression (2000) (0)
INHIBITORY EFFECT OF HIGH DENSITY LIPOPROTEIN HDL3 ON CYCLIC AMP ACCUMULATION IN RAT ADIPOCYTES : POSSIBLE INVOLVEMENT OF A PERTUSSIS TOXIN-SENSITIVE G-PROTEIN (1996) (0)
Lipoprotein(a) as a marker for coronary heart disease. (1996) (0)
4P-0986 The thioredoxin reductase/thioredoxin systems is upregulated in atherosclerotic plaques: Specific induction in human macrophages by oxidized low density lipoproteins (2003) (0)
[New method of determination of the lipase activity of the serum. Clinical applications]. (1974) (0)
[Study of changes in lipoprotein-lipase activity of adipose tissue and myocardium as a function of nutritional state in rats]. (1972) (0)
Commentary Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction (2010) (0)
Subject Index Vol. 43, 2006 (2006) (0)
[Inhibition by "essential" phospholipids of the bactericidal effect of cetylpyridinium chloride on common bacteria. Short communication]. (1977) (0)
Human Nutrition and Metabolism The Plasma and Lipoprotein Triglyceride Postprandial Response to a Carbohydrate Tolerance Test Differs in Lean and Massively Obese Normolipidemic Women 1 (2002) (0)
Peroxisome proliferator activated receptors and energy metabolism (2005) (0)
87 Clinical importance of new insights into the mechanism of activation of fibrates (1997) (0)
1SOA03-2 PPAR alpha agonists, HDL-C and the metabolic syndrome (2003) (0)
A need to redefine the consensus on the use of statins in coronary heart disease prevention. (2000) (0)
1.P.9 Structural aspects of the apolipoprotein CIII (1997) (0)
New variants of apolipoprotein (1995) (0)
2P-0462 Impact of adipophilin expression on lipid accumulation in human macrophages: Potential role in atherogenesis (2003) (0)
[Transfer of plasma cholesterol and atherosclerosis]. (1994) (0)
Induction of the plasma phospholipid transfer protein (PLTP) gene accounts for the HDL enlargement in mice treated with fenofibrate. Lack of HDL size redistribution in treated PLTP-deficient mice (2001) (0)
DISTRIBUTION OF LIPID VARIABLES IN SUBJECTS IN BELFAST, NORTHERN-IRELAND AND TAIYUAN, PEOPLES-REPUBLIC-OF-CHINA (1993) (0)
[Analysis of lipoproteins using polyacrylamide gel electrophoresis and fractionated precipitation with polyanions and detergents. Use in the classification of hyperlipoproteinemias]. (1976) (0)
Enzymo-immunoassay (EIA) for human apolipoprotein B. (1978) (0)
13th all Ireland social medicine meeting (1994) (0)
[Quantitative and qualitative variations of plasma free fatty acids under the effect of an orally administered excess of lipids in normal humans]. (1971) (0)
PlasmaApolipoprotein Concentrations inYoung Adults Witha Parental History ofPremature Coronary HeartDisease andinControl Subjects TheEARSStudy (2011) (0)
[Cholesterol: from where does it come, how does it circulate, where does it go?]. (1989) (0)
[Effect of clofibrate on blood and tissue lipids in rats on a normal and on a cholesterol-enriched diet]. (1977) (0)
Molecular mechanisms of action of fenofibrate (1998) (0)
[Plasma lipids. Technics of exploration. Classification of hyperlipemia]. (1975) (0)
Polyclonal and monoclonal antibody mapping of lipoprotein particles. Clinical applications. (1988) (0)
T01-P-015 Adenoviral-mediated over expression ofhuman adipophilin increases lipid storage in THP-1 macrophages (2005) (0)
Studies on human apo A-I transgenic mice showing the correlation of the antiatherogenic role of apo A-I with the presence of lipoproteins with pre-β mobility (1994) (0)
4.P.257 Moderate alcohol consumption in healthy volunteers reduced plasma clearance of apolipoprotein A-II (1997) (0)
Direct characterization, enrichment and sequencing of differential displayed cDNA sequences (1998) (0)
EFFECT OF ALPHA -TOCOPHEROL ON HDL OXIDATION (1998) (0)
[Value and significance of a hyperlipemia test by venous approach in the study of hyperlipemia. Study of it's variation under the effect of alcohol]. (1974) (0)
Triglyceride and VLDL-triglyceride responses to carbohydrate or fat is different in non-diabetic obese and lean women (2000) (0)
1.P.88 Combined hyperlipidemia induced by the expression of human Apo A-I/C-III/A-IV cluster in transgenic mice (1997) (0)
Impaired adaptive response to fasting in FXR-deficient mice (2005) (0)
Running title: Postprandial apoA-V in type 2 diabetes (2007) (0)
Contents, Vol. 15, 1973 (1973) (0)
[Hyperlipemia and lipoproteinogram]. (1974) (0)
[Lipoprotein metabolism]. (1973) (0)
[Mechanism of action of hypolipemic drugs]. (1992) (0)
[Type IIa dyslipoproteinemia. Effects of simvastatin and bezafibrate on atherogenic and non-atherogenic lipoprotein particles]. (1988) (0)
Blood-Brain Barrier in Vitro: Pharmaceutical Applications (1991) (0)
Influence of shift work, BMI, smoking and dietary intake on triglyceride-rich lipoparticles (1996) (0)
[Biological banks of the prospective cohort PRIME Study]. (2003) (0)
Effects of F 12511, a potent ACAT inhibitor, on human adrenocortical cells in culture (1999) (0)
Fatty acids as transcriptional regulators of the lipoprotein lipase and apo C-III genes: consequences for plasma triglyceride metabolism (1996) (0)
Chapter 4. Laboratory Measurement of Plasma Lipids and Lipoproteins (2019) (0)
Low-Density Lipoprotein for Delivery of an Acrylophenone Antineoplastic Molecule into Malignant Cells 1 (2006) (0)
Mechanisms of the hypolipidemic action of fibrates (1998) (0)
Phosphorylation-dependent down-regulation of apolipoprotein A5 by 1 insulin 2 3 (2004) (0)
W12-P-037 An increased susceptibility of LDL to oxidation in mice treated with a melatonin-related compound is not associated with progression of atherosclerosis (2005) (0)
Role of Apolipoprotein a IV in Promotion of Cellular Cholesterol Efflux from Adipose Cells (1989) (0)
Effects of alcohol on lipids and lipoprotein metabolism. (2000) (0)
Molecular analysis of lipoproteins: clinical applications. (1987) (0)
4.P.304 HDL (high density lipoprotein) and LDL (low density lipoprotein) receptors regulation in human adrenal cortex (1997) (0)
PPARα controlling HDL metabolism and atherosclerosis (2004) (0)
Farnesoid X receptor (FXR) regulates peripheral insulin sensitivity (2005) (0)
Apolipoprotein C-III, an important player in lipoprotein metabolism (1996) (0)
[Impact, on blood and tissue lipids, of an artificial lipid emulsion combined with essential amino acids and sorbitol, used in humans in exclusive parenteral feeding]. (1976) (0)
[Fluorimetric automatic enzymatic dosage of serum total cholesterol (author's transl)]. (1975) (0)
Apolipoprotein AII is a better ligand than apolipoprotein AI for the human HDL receptor SR-BI but alters specific cholesteryl ester uptake in human adrenal cell line (1999) (0)
Study of the biosynthesis of lipoproteins rich in triacylglycerides during experimental malaria in rodents. (1980) (0)
Molecular analysis of HDL particles. Clinical applications. (1989) (0)
PPAR-alpha activator (fenofibrate) restores endothelium responses in spontaneous hypertensive rat (2000) (0)
[Symptomatologic value of apolipoproteins]. (1985) (0)
[Separation of lipoproteins as a function of their apolipoprotein composition. Clinical applications]. (1986) (0)
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. (2014) (0)
1.P.231 A common Ile405Val mutation in the cholesteryl ester transfer protein (CETP) gene associated with longevity (1997) (0)
[New method for rapid and precise determination of serum lipase]. (1972) (0)
diabetes RECORD : Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes ACCORD : Action to Control Cardiovascular Risk in diabetes ACT NOW : Act Now for the Prevention of Type 2 Diabetes (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jean‐charles Fruchart?

Jean‐charles Fruchart is affiliated with the following schools:

Tufts University

Jean‐charles Fruchart's Academic­Influence.com Rankings

Jean‐charles Fruchart's Degrees

Why Is Jean‐charles Fruchart Influential?

Jean‐charles Fruchart's Published Works

Published Works

What Schools Are Affiliated With Jean‐charles Fruchart?

Jean‐charles Fruchart's AcademicInfluence.com Rankings